In inflammation, hypoxia, ischemia and malignant tumors, and eATP levels increase significantly [14,15], however the synergistic enzymatic activity of CD39/CD73 pathway degrades eATP and produces immunosuppressive Ado in TME [16,17], which inhibits the anti-tumor immunity [18]. This evidence concerns the gene ENTPD1 and cancer.